Reimbursement Lag of New Drugs Under Taiwan's National Health Insurance System Compared With United Kingdom, Canada, Australia, Japan, and South Korea
Drug lag-delayed approval or reimbursement-is a major barrier to accessing cutting‐edge drugs. Unlike approval lag, reimbursement lag is under‐researched. We investigated the key determinants of reimbursement lag under Taiwan National Health Insurance (NHI), and compared this lag with those in the U...
Saved in:
Main Authors: | Yi‐Ru Shih (Author), Kai‐Hsin Liao (Author), Yen‐Hui Chen (Author), Fang‐Ju Lin (Author), Fei‐Yuan Hsiao (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2020-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Medicines pricing and reimbursement in Canada
by: Chris BONNETT, et al.
Published: (2022) -
Neonatal Outcomes of Extremely Preterm Infants from Taiwan: Comparison with Canada, Japan, and the USA
by: Bai-Horng Su, et al.
Published: (2015) -
Mandated Health Insurance and Provider Reimbursement via Private Insurance
by: Andrew Friedson, et al.
Published: (2017) -
Variations in hip fracture inpatient care in Japan, Korea, and Taiwan: an analysis of health administrative data
by: Hongsoo Kim, et al.
Published: (2021) -
Approval, reimbursement and pricing of high-cost cancer medicines in Australia
by: Agnes Vitry
Published: (2015)